The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Synthego, a Bay Area biotech startup that won hundreds of millions of dollars in funding for its gene editing products and ...

New Orleans biotech South Rampart Pharma advances non-opioid pain drug with $8M funding from Ochsner Ventures and Gulf South ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

A Philadelphia entrepreneur developing eye repair tech stood out among international contenders as it gears up to raise a ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...